
Ocugen’s COVID-19 Vaccine Co-Development Partner Shares Phase 3 Interim Results
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from …
Read More